Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 236
- Registration Number
- NCT06551246
- Locations
- 🇩🇰
Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Aarhus N, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Pediatric and Adolescent medicine, Esbjerg Hospital, Esbjerg, Denmark
Efficacy and Safety of VDS+SU in the Treatment of OAB-dry in Children
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Xing Liu
- Target Recruit Count
- 180
- Registration Number
- NCT06489951
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 216
- Registration Number
- NCT06465576
- Locations
- 🇩🇰
Department of Pediatric and Adolescent medicine, Esbjerg Hospital, Esbjerg, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Aarhus N, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Xing Liu
- Target Recruit Count
- 150
- Registration Number
- NCT06201013
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 132
- Registration Number
- NCT04437108
- Locations
- 🇪🇬
Urology and Nephrology center, Mansoura, Egypt
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04023253
- Locations
- 🇨🇳
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan
Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2022-02-04
- Target Recruit Count
- 282
- Registration Number
- NCT03787654
- Locations
- 🇨🇳
Guang An Men Hospital, Beijing, China
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2018-08-02
- Target Recruit Count
- 110
- Registration Number
- NCT03468465
- Locations
- 🇪🇸
Hospital Clínico Universtario Virgen de la Arrixaca, El Palmar, Murcia, Spain
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 77
- Registration Number
- NCT03149809
- Locations
- 🇺🇸
Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States
🇺🇸Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States
🇺🇸Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.